TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients admitted with acute coronary syndrome (ACS) as the primary reason for hospital admission and use the VA for their usual source of care, defined as having 1 primary care visit within the 12 months prior to hospital admission will be screened for eligibility to participate. ACS is defined as acute myocardial infarction (both ST-elevation MI and non-ST elevation MI) or unstable angina. The presence of acute myocardial infarction will be defined using standard definitions from an international consensus statement, based on the following: a rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the upper reference limit and at least one of the following:~* symptoms of ischemia;~* ECG change indicative of new ischemia (new ST-T changes or new left bundle branch block);~* development of pathological Q waves in the ECG; or~* imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.42 Unstable angina will be defined by presence of ischemic symptoms and ECG changes indicative of new ischemia but without biomarker evidence of myonecrosis (i.e., biomarker elevation) and no evidence of new pathological Q waves, loss of viable myocardium or regional wall motion abnormality.~Exclusion Criteria:~* Patient admitted for primary non-cardiac diagnosis and develop ACS as a secondary condition (e.g. perioperative MI);~* planned discharge to nursing home or skilled nursing facility;~* irreversible, non-cardiac medical condition (e.g. metastatic cancer) likely to affect 6-month survival or ability to execute study protocol;~* lack of telephone/cell phone;~* VA is not primary source of care;~* regularly fill medications at non-VA pharmacy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
- Arm 2 (Type: ACTIVE_COMPARATOR): Patients will receive usual care following ACS hospital discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Entecavir for Decompensated HBV Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with decompensated liver cirrhosis and~* Replicative HBV infection (HBsAg positive, serum HBV DNA titer \>100,000 IU/mL) regardless of HBeAg and anti-HBe test results~Exclusion Criteria:~* prior exposure to NAs or other specific treatment for HBV infection (e.g. pegylated interferon)~* hepatocellular carcinoma~* co-infection with any other hepatotropic viruses or HIV~* acute-on-chronic liver failure as defined by Asia-Pacific Association for the Study of Liver criteria~* significant alcohol intake or another concomitant hepatobiliary disease~* expected survival below 4 weeks (e.g. hemodynamic instability, active sepsis, hepatorenal syndrome, etc)~* use of immunosuppressive medication or~* portal vein thrombosis.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETV 0.5 mg (Type: None): Group of study participants who were started on 0.5 mg/day of entecavir
- ETV 1.0 mg (Type: None): Group of study participants who were started on 1.0 mg/day of entecavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical and laboratory diagnosis of cystic fibrosis~* Age greater than or equal to 5 years~* Forced expiratory volume in 1 second (FEV1) greater than or equal to 40% predicted~* Sinus surgery within one week of enrollment~Exclusion Criteria:~* Pregnancy~* Intolerance of orally inhaled Pulmozyme (dornase alfa)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulmozyme (Type: EXPERIMENTAL): 2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
- placebo (Type: PLACEBO_COMPARATOR): 2.5 mg/2mL placebo administered intranasally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a Body Mass Index (BMI) of less than or equal to 26 kg/m2 at screening~* Subject is judged to be in good health~* Subject has been a nonsmoker for at least 3 months~* Subject is willing to avoid strenuous physical activity for the duration of the study~Exclusion Criteria:~* Subject has a history of high blood pressure requiring treatment~* Subject has a history of diabetes or a family history of diabetes mellitus~* Subject is unable to discontinue all prescription and non-prescription drugs for duration of study~* Subject consumes more than 3 alcoholic beverages per day~* Subject consumes more than 6 servings of caffeinated beverages per day (1 serving = 120mg caffeine)~* Subject has had major surgery or has donated or loss 1 unit of blood within 4 weeks of screening~* Subject has multiple and/or severe allergies to foods or drugs~* Subject is a regular user of illegal drugs~* Subject is unwilling or unable to consume the standardized meals during the study and/or is on a carbohydrate restricted diet

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): exenatide 5mcg
- 2 (Type: ACTIVE_COMPARATOR): exenatide 1.5mcg
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Equivalence Study of Dorzolamide 2% Eye Drops Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients of any race aged 18 years or older~* A clinical diagnosis of open angle glaucoma, pseudoexfoliation or pigment dispersion glaucoma, or ocular hypertension in one or both eyes~* IOP controllable on one drug treatment in the study eye in way that assures clinical stability of vision and the optic nerve throughout the study~* Baseline IOP between 18 and 32 mmHg in the study eye (in eyes not included in the study IOP must have been controllable on no pharmacologic treatment or on the study medicine only)~* Best corrected visual acuity of 20/200 or better in the study eye(s)~* Ability of subject to understand character and individual consequences of clinical trial~* Signed and dated informed consent of the subject must be available before start of any specific trial procedures~* Women with childbearing potential have to practicing a medically accepted contraception during trial and a negative pregnancy test (serum or urine) should be existent before trial. Reliable contraception are systemic contraceptives (oral, implant, injection) and diaphragm or condoms with spermicidal. Women that are sterile by surgery or for more than two years postmenopausal can be participate in the trial.~Exclusion Criteria:~* Chronic or recurrent inflammatory eye disease~* Ocular trauma within the past six months~* Current ocular infection, i.e. conjunctivitis or keratitis~* Any abnormality preventing reliable applanation tonometry~* Intraocular surgery or laser treatment within the past three months~* Inability to discontinue contact lens wear during the study~* Use of any systemic medication that would affect IOP with less than a~  1-month stable dosing regimen before the screening visit~* Pregnancy and lactation~* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product~* Participation in other clinical trials during the present clinical trial or within the last four weeks~* Medical or psychological condition that would not permit completion of the trial or signing of informed consent~* Subject is allergic to sulfonamides~* Severe renal dysfunction or hyperchloraemic acidosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dorzolamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infertile lean women with PCOS as defined by the Rotterdam criteria.~* CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).~Exclusion Criteria:~* Age \< 20 or \> 35 years.~* Presence of any infertility factor other than anovulatory PCOS.~* Previous history of ovarian surgery or surgical removal of one ovary.~* Previous exposure to cytotoxic drugs or pelvic irradiation.~* Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months.~* Metabolic or hormonal abnormalities.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Clomiphene citrate-HCG group (Type: ACTIVE_COMPARATOR): Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
- Clomiphene citrate group (Type: ACTIVE_COMPARATOR): Women will receive clomiphene citrate alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* -Written informed consent must be obtained before any assessment is performed.~* Male and female patients ≥ 18 years of age.~* Diagnosis of HS ≥ 1 year prior to baseline.~* Patients with moderate to severe HS defined as:~* A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules AND~* Inflammatory lesions should affect at least 2 distinct anatomic areas~* Patients agree to daily use of topical over-the-counter antiseptics on the areas affected by HS lesions while on study treatment.~Exclusion Criteria:~* Total fistulae count ≥ 20 at baseline.~* Any other active skin disease or condition that may interfere with assessment of HS.~* Active ongoing inflammatory diseases other than HS that require treatment with prohibited medications.~* Use or planned use of prohibited treatment. Washout periods detailed in the protocol have to be adhered to.~* History of hypersensitivity to any of the study drug constituents.~* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 1 (Type: ACTIVE_COMPARATOR): Secukinumab 300mg every 2 weeks
- Secukinumab 2 (Type: ACTIVE_COMPARATOR): Secukinumab 300mg every 4 weeks
- Placebo 1 (Type: PLACEBO_COMPARATOR): Placebo group to secukinumab 300mg every 2 weeks
- Placebo 2 (Type: PLACEBO_COMPARATOR): Placebo group to secukinumab 300mg every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients attending the GI Clinic at CCF who are prescribed colonoscopy and are willing to get the procedure done in the afternoon.~Exclusion Criteria:~* Colonoscopy is contraindicated~* Prior Colectomy or colon surgery.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Polythylene Glycol (PEG) in the evening (Type: ACTIVE_COMPARATOR): Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.~'Polyethylene Glycol afternoon'
- Polythylene Glycol (PEG) in the Morning (Type: EXPERIMENTAL): Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.~'Polyethylene Glycol morning'

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who fulfil the diagnostic criteria of HLH.~Exclusion Criteria:~* Prior cytotoxic or cyclosporin treatment for HLH.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids (Type: EXPERIMENTAL): As compared to the HLH-94 treatment, the main changes are that~1. Cyclosporin A is administered from day 1 and~2. Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Collagen-thrombin Matrix Efficacy During Cardiac Surgery: a Prospective Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. patients aged 19 years or older~2. undergoing elective OPCAB surgery with multi-vessel coronary artery disease.~Exclusion Criteria:~1. patients were pregnant~2. had a known sensitivity to any components of the bovine thrombin preparations or the porcine origin materials.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm label- Collastat® (Type: EXPERIMENTAL): None
- Control arm label- Floseal® (Type: ACTIVE_COMPARATOR): an marketed product is Floseal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Any stage with an estimated risk of node involvement at least 15% (and therefore at significant risk for local and/or systemic failure) based on pretreatment PSA and Gleason score (GS), e.g.: GS of 7 and PSA greater than 7.5 ng/mL GS of 6 and PSA greater than 22.5 ng/mL GS of 5 and PSA greater than 37.5 ng/mL PSA greater than 4 and less than 100 ng/mL Highest pretreatment value determined by a monoclonal assay that has a normal range of 0-4 ng/mL PSA measured by polyclonal assay (e.g., Yang) that has a normal range of 0-2.5 ng/mL may need to be divided by a conversion factor of approximately 1.5 GS determination required prior to entry No distant metastases No biopsy proven lymph node involvement Ineligible for protocol RTOG-9408 (clinical stages T2c-T4 with GS of 6 or higher are eligible for this study)~PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 70-100% Hematopoietic: Not specified Hepatic: Liver function tests no greater than 1.2 times normal Renal: Not specified Other: No major medical or psychiatric illness that would prevent completion of treatment or interfere with follow-up No second malignancy within 5 years except superficial nonmelanomatous skin cancer~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: At least 90 days since testosterone At least 60 days since finasteride Radiotherapy: No prior radiotherapy Surgery: No more than 60 days since surgical staging No radical surgery or cryosurgery

- Gender: MALE
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
- Arm 2 (Type: EXPERIMENTAL): Neoadjuvant TAS given 2 months before and during RT to the prostate only.
- Arm 3 (Type: EXPERIMENTAL): RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
- Arm 4 (Type: EXPERIMENTAL): RT to the prostate only followed by 4 months of TAS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Temsirolimus to Treat Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent must be given prior to study inclusion~* Histological or cytological confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC)~* Measurable progressive disease after platinum-based radiochemotherapy or recurrence or metastatic progressive disease after 1st line platinum-based chemotherapy~* Patients with loco-regional recurrence need to be progression free for at least 6 months after platinum-based radiochemotherapy, if locoregional recurrence is the only lesion~* Cetuximab must have been included in at least one prior line of therapy~* Disease is not amenable to surgery, radiotherapy or platinum-based chemotherapy~* At least one measurable lesion according to RECIST (Version 1.0) criteria~* Age \> 18 years~* ECOG performance status 0-2~* Brain metastases require completion of local therapy with discontinuation of steroids prior to start of treatment~* If of childbearing potential, willingness to use effective contraceptive method (double barrier method) for the study duration and 2 months after last dose~* Willingness and ability to comply with the protocol~* Adequate bone marrow function, liver and renal function~Exclusion Criteria:~* Live expectancy less than 3 months~* Anticancer treatment during the last 30 days prior to start of treatment, including systemic therapy, radiotherapy or major surgery~* Participation in a clinical trial within the last 30 days prior to study treatment~* Serious illness or medical condition other than the disease under study~* Other malignancies within 3 years, with exception of HNSCC, history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Inability to potentially complete follow up and treatment per protocol for psychological, familial, sociological or geographical reasons~* Pregnancy or breast feeding~* Known allergic/hypersensitivity reaction to any component of the treatment~* Concurrent treatment with oral anticoagulants~* Uncontrolled diabetes: fasting serum glucose \> 2.0 ULN~* Active or uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temsirolimus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete